Compare HIVE & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIVE | LXRX |
|---|---|---|
| Founded | 1987 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 996.7M |
| IPO Year | 2017 | 2000 |
| Metric | HIVE | LXRX |
|---|---|---|
| Price | $2.89 | $1.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $7.00 | $4.55 |
| AVG Volume (30 Days) | ★ 10.2M | 2.9M |
| Earning Date | 11-13-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $297,791,000.00 | $49,803,000.00 |
| Revenue This Year | $24.05 | N/A |
| Revenue Next Year | $40.34 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 158.32 | 60.24 |
| 52 Week Low | $1.73 | $1.10 |
| 52 Week High | $7.84 | $2.68 |
| Indicator | HIVE | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.16 | 32.50 |
| Support Level | $2.86 | $1.50 |
| Resistance Level | $3.30 | $1.81 |
| Average True Range (ATR) | 0.17 | 0.13 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 7.10 | 6.32 |
HIVE Digital Technologies Ltd is a sustainable-energy-focused digital infrastructure company that provides infrastructure solutions through the operation of Tier-1 and Tier-3 data centers. Its computing power is used for high-performance computing (HPC) and for generating hashrate sold to mining pools for cryptocurrency mining. The Company uses cash flow from its hashrate services business to support the expansion of its AI and HPC operations through its subsidiary. The Company focuses on Canada, Sweden, and Paraguay, where low-cost renewable power supports its operations and expansion. It operates in one segment with two revenue streams: the mining and sale of digital currencies and high-performance computing hosting. The majority of its revenue is generated from Bermuda.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.